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Abstract
Background: Multiple factors are involved in asthma exacerbations, including environmental exposure and viral
infections. We aimed to assess the association between severe asthma exacerbations, acute respiratory viral
infections and other potential risk factors.
Methods: Asthmatic children aged 4–14 years were enrolled for a period of 12 months and divided into two
groups: those with exacerbated asthma (group 1) and non-exacerbated asthma (group 2). Clinical data were obtained
and nasopharyngeal samples were collected through nasopharyngeal aspirate or swab and analysed via indirect
fluorescent immunoassays to detect influenza A and B viruses, parainfluenza 1–3, adenovirus and respiratory syncytial
virus. Rhinovirus was detected via molecular assays. Potential risk factors for asthma exacerbation were identified in
univariate and multivariate analyses.
Results: In 153 children (group 1: 92; group 2: 61), median age 7 and 8 years, respectively, the rate of virus detection
was 87.7%. There was no difference between groups regarding the frequency of virus detection (p = 0.68); however,
group 1 showed a lower frequency (19.2%) of inhaled corticosteroid use (91.4%, p < 0.01) and evidence of inadequate
disease control. In the multivariate analysis, the occurrence of three or more visits to the emergency room in the past
12 months (IRR = 1.40; p = 0.04) and nonadherence to inhaled corticosteroid (IRR = 4.87; p < 0.01) were the only factors
associated with exacerbation.
Conclusion: Our results suggest an association between asthma exacerbations, poor disease control and
nonadherence to asthma medication, suggesting that viruses may not be the only culprits for asthma exacerbations in
this population.
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Background
Asthma exacerbations generate considerable morbidity, af-
fecting various aspects of the patient’s quality of life, and
producing high costs for the health system [1]. The multi-
factorial origin of asthma exacerbations has been well
described and includes allergen exposure, acute viral re-
spiratory tract infections, pollutants, climate changes, exer-
cise, amongst other factors [1–3]. Despite the existence of
effective drugs, poor asthma control remains common in
many children worldwide [4]. A key characteristic of
poor asthma control is the occurrence of asthma exacerba-
tions, and a history of recent emergency room visits for
asthma is a strong and independent predictor of future
asthma exacerbations [5]. Asthma tends to be poorly con-
trolled in the socially disadvantaged population [6] and the
reasons are multifactorial with complex interactions [7]. On
the other hand, authors have identified specific genetic vari-
ants associated with susceptibility to viral respiratory infec-
tions, severity of infection and virus-induced exacerbations
of asthma during childhood [8].
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Since the early 1970s, viral respiratory infections have
been associated with the onset of asthma exacerbations.
However, studies in children, who are particularly suscep-
tible to viral infection due to their relative immunological
immaturity, increased in the 1990s, when molecular tech-
niques became more sensitive allowing for the identifica-
tion of more respiratory viruses and facilitating a better
understanding of this association [9–16]. Studies using re-
verse transcription-polymerase chain reaction (RT-PCR)
detected respiratory viruses in more than 90% of asthma
exacerbations [9].
Acute respiratory tract infections are responsible for
high morbidity and mortality, accounting for around 20%
of the estimated 9 million deaths of children worldwide in
2007, according to the World Health Organization. Vi-
ruses are responsible for most of these infections, causing
generally mild and self-limited infections, though some
may become very severe or complicate the clinical course
of patients with underlying chronic lung diseases, includ-
ing asthma [17]. Moreover, the association between viral
infection and environmental exposure is described as a
trigger for exacerbations and type 2 inflammation is asso-
ciated with an increased risk of virus-induced exacerba-
tions [18, 19]. Achieving asthma control remains a global
challenge, especially in poor-resource populations. Al-
though viral infection is an important trigger, few studies in
this area have been conducted in tropical countries. To add
more details about this possible association in Latin Ameri-
can children, we examined the viral detection rate in a
group of Brazilian asthmatic children with and without ex-
acerbation. We hypothesize that in a population of a low
income country, living in a subtropical area, viruses may
not be the main trigger of an asthmatic exacerbation.
Methods
Setting
This study was carried out in the city of Goiânia, capital
of Goiás state, located in Central Brazil, a region with
semi-humid tropical climate with an estimated population
of 1,302,001 inhabitants. Public health care is provided
free of charge by the Brazilian Unified Health System, and
an estimated 70% of the population use the public health
system [20].
Study population
From June 2012 through August 2013, asthmatic
children were screened for respiratory viruses if they
met the following inclusion criteria: 4–14 year olds,
admitted to emergency rooms of three hospitals, which at-
tend children from public and private health insurance
due to asthma exacerbation (group 1). We only included
in the study patients who had at least three previous epi-
sodes of bronchospasm and fulfill the GINA criteria for
asthma definition [1]. We did not include children under
4 years old because of the difficulty in differentiation of
asthma from wheezing episodes of other origin in very
young children. Exacerbations were defined as increased
symptoms that required a change in medication as judged
by the attending physician according to ATS/ERS state-
ment [21]. Exacerbations requiring a course of oral corti-
costeroids or admission to hospital were considered
severe.
Asthmatic children without exacerbation (group 2), were
invited to participate in this study during their appointment
in the major respiratory outpatient clinic of the city, which
attend children from public health insurance (Brazilian
Unified Health System). They were only eligible for in-
clusion when they reported not having symptoms of
upper respiratory tract infection, such as rhinorrhoea,
fever and nasal congestion in the 4 weeks prior to the
clinic visit. All patients had similar access to primary care
and maintenance medications. Exclusion criteria for both
groups were premature birth and the presence of cardiore-
spiratory chronic diseases, neurologic and metabolic disor-
ders and immunosuppression.
The study protocol was approved by the Clinical Re-
search Ethics Committee (HC/UFG Protocol 175/2011).
Written informed consent was obtained from parents, and
written assent was obtained from older children (over
8 years old).
Data and sample collection
For each child, data on sociodemographic data, asthma re-
lated symptoms, hospitalisations in the last 12 months
and environmental exposure to aeroallergens and second-
hand tobacco was collected by two researchers (LDCC
and PSSC). A nasopharyngeal aspirate was obtained
from each patient upon admission to the emergency
ward (Group 1) or during the interview (Group 2).
The nasopharyngeal swab specimens were obtained
from the nostril from a depth of 2 to 3 cm by using
a sterile ray swab that was then inserted into a vial
containing 2.5 ml of viral transport medium (MEM).
For the nasopharyngeal aspirate, a disposable cath-
eter connected to a mucus extractor was inserted
into the nostril to a depth of 5 to 7 cm and drawn
back while applying gentle suction with an electric
suction device [22]. Nasopharyngeal flocked swab
(Chemicon-Millipore Corporation, Billerica, MA,
USA) was obtained in cases of absence of sufficient sam-
ple by nasopharyngeal aspirate.
Samples were transported at 4 °C to the Human Vir-
ology Laboratory, Federal University of Goias, Trop-
ical Medicine and Public Health Institute and
processed immediately. The supernatant was stored at −
70 °C for molecular study, and the pellet was used in the
immunofluorescence assay.
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Viral detection
Each sample was analysed using a Respiratory Panel I
Viral Screening and Identification IFA Reagent immuno-
fluorescence kit (Chemicon-Millipore Corporation, Bil-
lerica, MA, USA) consisting of a panel of monoclonal
antibodies specific to influenza virus A (FLUVA), influ-
enza virus B (FLUVB), human respiratory syncytial virus
(hRSV), human adenovirus (hADV), and human para-
influenza viruses (hPIV) 1, 2, and 3 following the man-
ufacturer’s instructions.
For molecular identification of rhinovirus, all samples
were submitted to ribonucleic acid (RNA) extraction using
a QIAamp® cador® Pathogen Mini Kit (Qiagen, Germany),
and conventional RT-PCR was conducted using primers
described previously [23]. Briefly, 20 μL of viral RNA was
extracted using random hexamers (Random Primer –
Invitrogen® life technologies, USA) in a final volume of
50 μL. The reaction was incubated at 25 °C for 5 min, 42 °
C for 10 min, 50 °C for 20 min, and 85 °C for 5 min, all in
a single cycle. For the polymerase chain reaction (PCR) re-
action, the commercial kit Platinum PCR SuperMix HF
(Invitrogen® life technologies, USA), 0.4 mM of each pri-
mer (P1–1 e P3–1), and 2.5 μL of cDNA were mixed and
submitted to amplification in a thermocycler (Mastercy-
cler Personal/Eppendorf) with the following cycling pa-
rameters: 94 °C for 2 min, followed by 35 cycles of 94 °C
for 20 s, 53 °C for 30 s, 72 °C for 40 s, and a final exten-
sion of 72 °C for 10 min. The products were submitted to
1.5% agarose gel electrophoresis and visualised using a UV
transilluminator. The samples were compared to a mo-
lecular marker (100 bp ladder), and the expected amplicon
size for Rhinovirus was 390 bp. In all reactions, positive
(previously sequenced Rhinovirus samples) and negative
(MilliQ water) controls were used.
Statistical analysis
Kruskal-Wallis, Chi-square and Fisher’s exact tests were
used to compare medians and proportions between
groups. Poisson multivariate regression analysis was per-
formed to identify the variables associated with the out-
come (asthma exacerbation), including the independent
variables significantly or near-significantly (p ≤ 0.1) in bi-
variate analysis. Results are presented as the incidence
risk ratio (IRR) with the 95% confidence interval (95%
CI). All analyses were performed using STATA v 12.0
(Stata Corp, College Station, TX, USA).
Results
During the study period, respiratory secretion samples
were collected from 158 children. Five patients (3.2%)
were excluded from analysis (three from group 1 and
two from group 2) due to an insufficient amount of ma-
terial for the examinations. Of the 153 samples analysed,
92 (60.1%) belonged to group 1 and 61 (39.9%) to group
2. The median age was 7.0 years (IQR =5.0–8.7) in
group 1 and 8.0 years (6.0–11.0) in group 2. Table 1
shows clinical and socio-demographic characteristics of
the patients in the study.
In 134 children (87.6%), the nasal sample was obtained
by nasopharyngeal aspirate and in 19 children (12.4%) by
nasal swab. Most patients (72.0%) were recruited between
April and June (autumn in the southern hemisphere); the
highest detection rate of viruses (63.2%) also occurs dur-
ing this time period.
Of the 153 samples tested, 136 were positive (88.9%; 95%
CI 83.1–93.2) for at least one virus, and the detection rate
of viruses was similar in both groups (p = 0.7). More than
one viral agent was identified in 27.9% (36) of the
samples, with no difference between groups (p = 0.1).
The most common virus was hRV (82.4, 95% CI 75.77–
87.8), followed by FLUVA (15.0%), hADV (6.5%), hPIV2
(4.6%), hRSV (3.9%), FLUVB (2.6%) and hPIV1 (2.6%).
None of the samples were positive for hPIV3. FLUVB and
hPIV1 were only found with other viruses (Table 2).
We performed an analysis of the severity of exacerba-
tions and did not find statistically significant differences
between the groups with and without virus infection re-
garding severity, such as hospitalization (p = 0.4), oxygen
use (p = 0.8), and systemic use of corticosteroids (p = 0.5).
There were no differences in the viral rates between chil-
dren with and without exacerbation. The results of univari-
ate analysis evidenced that some variables were associated
with asthma exacerbation: at least one hospitalisation for
asthma in the past 12 months, at least three emergency
room visits in the past 12 months, white ethnicity, monthly
family income below 200 US$, cough or dyspnoea on exer-
tion, nocturnal cough, exposure to mould and poor medi-
cation adherence (Table 1). After multivariate analysis, at
least three visits to hospital for asthma in the last
12 months and nonadherence in inhaled corticosteroids
(ICS) remained associated with the outcome (Table 3).
Discussion
In this study, we assessed asthmatic children in emergency
room and in an outpatient clinic from a tropical region in
Brazil and the results were consistent with those observed
by several authors around the world, with high viral detec-
tion rates [9–11], with rhinovirus being the most frequent
agent similar with others studies [9, 12, 15, 16, 23–25].
However the presence of respiratory viruses was
similar in children with and without asthma exacer-
bation (regardless of severity) and although most studies
have shown a higher prevalence of viruses in patients with
acute asthma than controls, others studies found a similar
detection rate of viruses between children with and without
exacerbation [26–29].
The high detection rate of viruses among patients
without asthma exacerbation may reflect the increased
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sensitivity of PCR, which detects nucleic acid from
current or previous infections, especially in the case of
rhinovirus, which may be present up to 5 to 6 weeks
after the beginning of symptomatic infection [30]. Re-
garding obtaining the sample, previous studies have shown
that diagnostic yields of nasopharyngeal swab are compar-
able to the results obtained with nasopharyngeal aspirate
specimens for all of the viruses identified by PCR methods
[31–33]. In the present study the rates of virus detection
was as high as in previous studies and rhinovirus was the
most prevalente, in both group, independent of the sample
colletion method.
Although it has been shown that viruses are associated
with asthma exacerbations, several studies suggest that
other factors, like allergen exposure, in combination with
viral infection may increase the risk. In the subjects of this
study, according to the results of bivariate analysis some
variables were associated with asthma exacerbation: at
least one hospitalization for asthma in the past 12 months,
at least three emergency room visits in the past 12 months,
white ethnicity, monthly family income below 200 US$,
cough or dyspnea on exertion, nocturnal cough, exposure
to mold and poor medication adherence. After multivari-
ate analysis, the variables that remained associated with a
higher risk of exacerbation were at least three emergency
visits due to exacerbation in the last 12 months and non-
adherence to asthma treatment.
It is known that exposure to allergens in combination
with viral infection may increase the likelihood of an ex-
acerbation, and in this population, allergic exposure was
more prevalent in the exacerbated group, although without
statistical significance. Exposure to mold was associated
with exacerbation in the univariate analysis, but this associ-
ation was not maintained in a multivariate analysis. We
know that asthma prevalence in tropical areas is high and it
may be linked to exposure to dust mites, parasitic infest-
ation and other unknown aspects [34]. Exposure to molds
is associated with allergic diseases, however, it prevalence
vary widely probably because of environmental differences,
and wide range of diagnostic tests used [2]. We assessed
aeroallergen exposure through a questionnaire, not with
objective measures, however, the results was similar to data
obtained by Brazilian studies, with sensitization prevalence
between 46.8% [35] and 54% [36] to at least one aeroaller-
gen in asthmatic children evaluated by skin prick test or
standard allergen extracts panel.
In the present study, nonadherence to inhaled cortico-
steroid was an important risk factor for asthma exacer-
bation, which indicates that the likelihood of viruses
triggering an exacerbation of asthma can be minimized
Table 1 Clinical and social demographic features of patients with and without exacerbation
G1 (92) G2 (61)
N (%) N (%) P
Male gender 56 (60.9) 42 (68.9) 0.20
White ethnicity 62 (67.4) 28 (45.9) < 0.01
Monthly family income ≤200 US$ 41 (44.6) 39 (63.9) 0.01
Maternal schooling level≤ 8 years 47 (51.1) 25 (41.0) 0.14
≥ 3 emergency room visits in the past 12 months 73 (76.0) 23 (24.0) < 0.01
1 or more hospitalisations for asthma in the past 12 months 58 (80.6) 14 (19.4) < 0.01
Cough or dyspnoea on exertion (yes) 66 (75.0) 22 (25.0) < 0.01
Nocturnal cough, in-between exacerbations (yes) 70 (80.5) 17 (19.5) < 0.01
Use of ICS (yes) 6 (19.2) 84 (91.4) < 0.01
Exposure to furry animals (yes) 58 (65.9) 30 (34.1) 0.09
Exposure to mould (yes) 44 (71.0) 18 (29.0) 0.02
Exposure to house dust mite (yes) 66 (59.5) 45 (40.5) 0.80
Exposure to second hand tobacco smoking (yes) 33 (56.9) 25 (43.1) 0.61
G1 group 1(exacerbated asthmatics), G2 group 2 (non-exacerbated asthmatics), ICS inhaled corticosteroids
Table 2 Rates of virus detection and co-detection between
groups
Virus G1 G2 Total
N (%) N (%) N (%) P
hRV 74 (80.4) 52 (85.2) 126 (82.4) 0.19
FLUVA 17 (18.5) 6 (9.8) 23 (15.0) 0.17
hAdV 5 (5.4) 5 (8.2) 10 (6.5) 0.30
HPIV2 6 (6.5) 1 (1.6) 7 (4.6) 0.20
hRSV 5 (5.4) 1 (1.6) 6 (3.9) 0.30
FLUV B 3 (3.3) 1 (1.6) 4 (2.6) 0.50
HPIV1 4 (4.3) 0 (0.0) 4 (2.6) 0.16
Any detected virus 81 (88.0) 55 (90.2) 136 (88.9) 0.70
Co-detection 27 (20.9) 9 (7.0) 36 (27.9) 0.10
G1 group 1, G2 group 2, hRV human rhinovirus, FLUVA influenza virus A, hAdV
human adenovirus, FLUVB influenza virus B, hRSV human respiratory syncytial
virus, HPIV2 human parainfluenza virus type 2, HPIV1 parainfluenza virus type 1
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by daily ICS controller therapy. Our results are in ac-
cordance with a study in the United Kingdom, in which
the regular use of daily ICS controller therapy protected
from virus-related asthma exacerbations and hospital ad-
missions [37].
Experimental studies have demonstrated that ICS
inhibit respiratory tract viral replication and reduce
cytokines in bronchial epithelial cells [38]. These effects of
reducing virus-induced inflammation may help to explain
the findings observed among patients using ICS in the
present study who, despite presence of viral genetic mater-
ial, showed no clinical evidence of viral disease. This associ-
ation may have previously gone unnoticed because most of
the studies in this area have been performed in countries in
which most if not all children with asthma in the studies
were on ICS maintenance treatment [7, 10, 14]. In contrast,
the present study was conducted in a different setting with
a lower rate of ICS use.
This is one of a few studies on viruses related to
asthma exacerbations in a low-middle income country
and using a control comparison group, which enhances
the relevance of the results. This study not only downplays
the importance of viruses as the sole culprit in asthma ex-
acerbations, but also highlights the need of a comparison
group in similar investigations. Moreover, it is possible
that different populations can behave differently in terms
of triggering exacerbations and genetic mechanisms may
be involved in the association [8, 34]. Thus, larger studies
are necessary to provide more insights into the pathogen-
esis of viral respiratory infections and virus-induced exac-
erbations of asthma in different populations.
In conclusion, while there is no doubt that viruses are as-
sociated with asthma exacerbations, the results of the
present study suggest that viral infections per se are insuffi-
cient to cause an exacerbation. The proportion of acute re-
spiratory viral infections among children with current
asthma exacerbation was similar to that observed among
children without exacerbation. The only significant risk
factors for acute asthma exacerbations were previous
emergency room visits for uncontrolled asthma and non-
adherence in asthma treatment. The present study sug-
gests that the occurrence of virus-induced exacerbations
in children can be attenuated by the proper use of inhaled
corticosteroids.
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